March 2016

New Product - Tybost

Tybost (cobicistat) is a selective, mechanism based inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A family. Inhibition of CYP3A mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as atazanavir or darunavir. Tybost is indicated as a pharmacokinetic enhancer of appropriate HIV‑1 protease inhibitors in adults. Tybost is contraindicated with the following medicines. Alpha1‑adrenoreceptor antagonist alfuzosin; anticonvulsants carbamazepine, phenobarbitone, phenytoin; antimycobacterials rifabutin, rifampicin, rifapentine; ergot derivatives dihydroergotamine, ergonovine, ergotamine, methylergonovine; gastrointestinal motility agent cisapride; herbal product St John’s wort; HMG‑CoA reductase inhibitors lovastatin, simvastatin; neuroleptic pimozide; phosphodiesterase‑5 (PDE‑5) inhibitors sildenafil and tadalafil for the treatment of pulmonary arterial hypertension; and orally administered sedative/hypnotics midazolam, triazolam. Tybost is available as 150 mg tablets in packs of 30’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629